Synthetic CBD as a Therapy for COVID-19

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The study aim to test proof of concept of CBD treatment for efficacy and safety in patients suffering with mild COVID-19 infection. The CBD will be delivered via oil droplets not containing THC, compared to placebo.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center

Criteria

Inclusion Criteria:

• COVID 19 patients

• 18 Years and older

Exclusion Criteria:

• Respiratory failure requiring mechanical ventilation

• Intensive care unit admission

• Neutrophile con. < 1000 cells/mm3

• Lymphocyte con < 500 cells/mm3

• Liver enzymes 5 times higher then the norm

• QT interval longer then 500 ms.

• Pregnancy

• Hemodialysis renal replacement therapy

• Active or prior psychotic event